MOUNTAIN VIEW, Calif. and ST GALLEN, CH , May 18, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from a forty-six (46) patient Phase II dose-ranging trial in the orphan kidney disorder, primary Focal
-- On track to file U.S. New Drug Application (NDA) for avacopan in ANCA-associated vasculitis mid-year -- -- Topline data from CCX140 LUMINA-1 Phase II clinical trial in Focal Segmental Glomerulosclerosis (FSGS) expected Q2 -- -- Completed enrollment of the AURORA clinical trial of avacopan in
MOUNTAIN VIEW, Calif. , May 04, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's first quarter 2020 financial results will be released after market close on Monday, May 11, 2020. ChemoCentryx executive management will host a conference call beginning
-- Announced positive topline data from pivotal Phase III ADVOCATE trial for ANCA-vasculitis in Q4; U.S. NDA filing expected mid-2020 -- -- “2020 4-Sight” on the horizon with topline data from four clinical trials expected in 2020: AURORA and ACCOLADE clinical trials of avacopan in Hidradenitis
MOUNTAIN VIEW, Calif. , March 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2019 financial results will be released after market close on Tuesday, March 10, 2020. ChemoCentryx executive management will host a
MOUNTAIN VIEW, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 9th Annual SVB Leerink Healthcare Conference on Wednesday, February 26, 2020 at 3:00 p.m. ET .
Non-dilutive funding vehicle strengthens balance sheet for registration filing of avacopan in ANCA vasculitis and anticipated approval and commercial launch MOUNTAIN VIEW, Calif. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (NASDAQ: CCXI) today announced that the Company has secured a
MOUNTAIN VIEW, Calif. , Jan. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 38th Annual JP Morgan Healthcare Conference on Wednesday January 15, 2020 at 1:30 p.m. PT .
MOUNTAIN VIEW, Calif. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 2:30 p.m. ET .
-- Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks -- -- Significantly reduced glucocorticoid toxicity -- -- Significantly improved kidney function compared to glucocorticoid-containing SOC
